# PRC-063 in an ADULT Workplace Environment

> **NCT02225639** · PHASE3 · COMPLETED · sponsor: **Rhodes Pharmaceuticals, L.P.** · enrollment: 60 (actual)

## Conditions studied

- Attention Deficit Hyperactivity Disorder (ADHD)

## Interventions

- **DRUG:** PRC-063 25 mg
- **DRUG:** Placebo
- **DRUG:** PRC-063 35 mg
- **DRUG:** PRC-063 45 mg
- **DRUG:** PRC-063 55 mg
- **DRUG:** PRC-063 70 mg
- **DRUG:** PRC-063 85 mg
- **DRUG:** PRC-063 100 mg

## Key facts

- **NCT ID:** NCT02225639
- **Lead sponsor:** Rhodes Pharmaceuticals, L.P.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2015-04
- **Final completion:** 2015-05
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2015-07-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02225639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02225639, "PRC-063 in an ADULT Workplace Environment". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT02225639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*